These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 23070117)

  • 1. T cells redirected to EphA2 for the immunotherapy of glioblastoma.
    Chow KK; Naik S; Kakarla S; Brawley VS; Shaffer DR; Yi Z; Rainusso N; Wu MF; Liu H; Kew Y; Grossman RG; Powell S; Lee D; Ahmed N; Gottschalk S
    Mol Ther; 2013 Mar; 21(3):629-37. PubMed ID: 23070117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T cells redirected to interleukin-13Rα2 with interleukin-13 mutein--chimeric antigen receptors have anti-glioma activity but also recognize interleukin-13Rα1.
    Krebs S; Chow KK; Yi Z; Rodriguez-Cruz T; Hegde M; Gerken C; Ahmed N; Gottschalk S
    Cytotherapy; 2014 Aug; 16(8):1121-31. PubMed ID: 24841514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma.
    Hegde M; Corder A; Chow KK; Mukherjee M; Ashoori A; Kew Y; Zhang YJ; Baskin DS; Merchant FA; Brawley VS; Byrd TT; Krebs S; Wu MF; Liu H; Heslop HE; Gottschalk S; Yvon E; Ahmed N
    Mol Ther; 2013 Nov; 21(11):2087-101. PubMed ID: 23939024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chimeric antigen receptor T-cell immunotherapy for glioblastoma: practical insights for neurosurgeons.
    Choi BD; Curry WT; Carter BS; Maus MV
    Neurosurg Focus; 2018 Jun; 44(6):E13. PubMed ID: 29852773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor activity of the third generation EphA2 CAR-T cells against glioblastoma is associated with interferon gamma induced PD-L1.
    An Z; Hu Y; Bai Y; Zhang C; Xu C; Kang X; Yang S; Li W; Zhong X
    Oncoimmunology; 2021; 10(1):1960728. PubMed ID: 34408922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression.
    Ahmed N; Salsman VS; Yvon E; Louis CU; Perlaky L; Wels WS; Dishop MK; Kleinerman EE; Pule M; Rooney CM; Heslop HE; Gottschalk S
    Mol Ther; 2009 Oct; 17(10):1779-87. PubMed ID: 19532139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants.
    Krenciute G; Prinzing BL; Yi Z; Wu MF; Liu H; Dotti G; Balyasnikova IV; Gottschalk S
    Cancer Immunol Res; 2017 Jul; 5(7):571-581. PubMed ID: 28550091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncolytic adenovirus and gene therapy with EphA2-BiTE for the treatment of pediatric high-grade gliomas.
    Arnone CM; Polito VA; Mastronuzzi A; Carai A; Diomedi FC; Antonucci L; Petrilli LL; Vinci M; Ferrari F; Salviato E; Scarsella M; De Stefanis C; Weber G; Quintarelli C; De Angelis B; Brenner MK; Gottschalk S; Hoyos V; Locatelli F; Caruana I; Del Bufalo F
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma.
    Bielamowicz K; Fousek K; Byrd TT; Samaha H; Mukherjee M; Aware N; Wu MF; Orange JS; Sumazin P; Man TK; Joseph SK; Hegde M; Ahmed N
    Neuro Oncol; 2018 Mar; 20(4):506-518. PubMed ID: 29016929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma.
    Morgan RA; Johnson LA; Davis JL; Zheng Z; Woolard KD; Reap EA; Feldman SA; Chinnasamy N; Kuan CT; Song H; Zhang W; Fine HA; Rosenberg SA
    Hum Gene Ther; 2012 Oct; 23(10):1043-53. PubMed ID: 22780919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors.
    Ahmed N; Salsman VS; Kew Y; Shaffer D; Powell S; Zhang YJ; Grossman RG; Heslop HE; Gottschalk S
    Clin Cancer Res; 2010 Jan; 16(2):474-85. PubMed ID: 20068073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engineering NK Cells Modified With an EGFRvIII-specific Chimeric Antigen Receptor to Overexpress CXCR4 Improves Immunotherapy of CXCL12/SDF-1α-secreting Glioblastoma.
    Müller N; Michen S; Tietze S; Töpfer K; Schulte A; Lamszus K; Schmitz M; Schackert G; Pastan I; Temme A
    J Immunother; 2015 Jun; 38(5):197-210. PubMed ID: 25962108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing EphA2-CAR T Cells for the Adoptive Immunotherapy of Glioma.
    Yi Z; Prinzing BL; Cao F; Gottschalk S; Krenciute G
    Mol Ther Methods Clin Dev; 2018 Jun; 9():70-80. PubMed ID: 29552579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL-13Rα2/TGF-β bispecific CAR-T cells counter TGF-β-mediated immune suppression and potentiate anti-tumor responses in glioblastoma.
    Hou AJ; Shih RM; Uy BR; Shafer A; Chang ZL; Comin-Anduix B; Guemes M; Galic Z; Phyu S; Okada H; Grausam KB; Breunig JJ; Brown CE; Nathanson DA; Prins RM; Chen YY
    Neuro Oncol; 2024 Oct; 26(10):1850-1866. PubMed ID: 38982561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chimeric Antigen Receptor T Cells in Glioblastoma-Current Concepts and Promising Future.
    Kringel R; Lamszus K; Mohme M
    Cells; 2023 Jul; 12(13):. PubMed ID: 37443804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Engager T cells: a new class of antigen-specific T cells that redirect bystander T cells.
    Iwahori K; Kakarla S; Velasquez MP; Yu F; Yi Z; Gerken C; Song XT; Gottschalk S
    Mol Ther; 2015 Jan; 23(1):171-8. PubMed ID: 25142939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of third generation anti-EGFRvIII chimeric T cells and EGFRvIII-expressing artificial antigen presenting cells for adoptive cell therapy for glioma.
    Sahin A; Sanchez C; Bullain S; Waterman P; Weissleder R; Carter BS
    PLoS One; 2018; 13(7):e0199414. PubMed ID: 29975720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma.
    Miao H; Choi BD; Suryadevara CM; Sanchez-Perez L; Yang S; De Leon G; Sayour EJ; McLendon R; Herndon JE; Healy P; Archer GE; Bigner DD; Johnson LA; Sampson JH
    PLoS One; 2014; 9(4):e94281. PubMed ID: 24722266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER2-targeting CAR-T cells show highly efficient anti-tumor activity against glioblastoma both in vitro and in vivo.
    Li X; Zhao L; Li W; Gao P; Zhang N
    Genes Immun; 2024 Jun; 25(3):201-208. PubMed ID: 38702509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization and Functional Analysis of scFv-based Chimeric Antigen Receptors to Redirect T Cells to IL13Rα2-positive Glioma.
    Krenciute G; Krebs S; Torres D; Wu MF; Liu H; Dotti G; Li XN; Lesniak MS; Balyasnikova IV; Gottschalk S
    Mol Ther; 2016 Feb; 24(2):354-363. PubMed ID: 26514825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.